Artificial intelligence-based model for the recurrence of hepatocellular carcinoma after liver transplantation

被引:2
|
作者
Altaf, Abdullah [1 ,2 ]
Mustafa, Ahmed [3 ]
Dar, Abdullah [2 ]
Nazer, Rashid [4 ]
Riyaz, Shahzad [5 ]
Rana, Atif [4 ]
Bhatti, Abu Bakar Hafeez [2 ,6 ]
机构
[1] King Edward Med Univ, Lahore, Pakistan
[2] Shifa Int Hosp, Dept HPB & Liver Transplant Surg, Sector H-8-4,Pitras Bukhari Rd, Islamabad 44000, Pakistan
[3] Natl Univ Sci & Technol, Dept Robot & Artificial Intelligence, Islamabad, Pakistan
[4] Shifa Int Hosp, Dept Radiol, Islamabad, Pakistan
[5] Shifa Int Hosp, Dept Gastroenterol & Hepatol, Islamabad, Pakistan
[6] Shifa Tameer E Millat Univ, Dept Surg, Islamabad, Pakistan
关键词
SELECTION CRITERIA; EXPANSION;
D O I
10.1016/j.surg.2024.07.039
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: Artificial intelligence-based models might improve patient selection for liver transplantation in hepatocellular carcinoma. The objective of the current study was to develop artificial intelligence-based deep learning models and determine the risk of recurrence after living donor liver transplantation for hepatocellular carcinoma. Methods: The study was a single-center retrospective cohort study. Patients who underwent living donor liver transplantation for hepatocellular carcinoma were divided into training and validation cohorts (n 1/4 192). The deep learning models were used to stratify patients in the training cohort into low- and highrisk groups, and 5-year recurrence-free survival was assessed in the validation cohort. Results: The median follow-up period was 59.1 (33.9-72.4) months. The artificial intelligence model (pretransplant factors) had an area under the curve of 0.86 in the training cohort and 0.71 in the validation cohort. The largest tumor diameter and alpha-fetoprotein level had the greatest Shapley Additive exPlanations values for recurrence (>0.4). The 5-year recurrence-free survival rates in the low- and highrisk groups were 92.6% and 45% (P < .001). In the second artificial intelligence model (pretransplant factors & thorn; grade), the area under the curve for the validation cohort was 0.77, with 5-year recurrence-free survival rates of 96% and 30% in the low- and high-risk groups (P < .001). None of the low-risk patients outside the Milan and University of California San Francisco Criteria had recurrence during follow-up. Conclusions: The artificial intelligence-based hepatocellular carcinoma transplant recurrence models might improve patient selection for liver transplantation. (c) 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
引用
收藏
页码:1500 / 1506
页数:7
相关论文
共 50 条
  • [21] Recurrence of hepatocellular carcinoma after liver transplantation: Is immunosuppression a factor?
    Schwartz, M
    Konstadoulakis, M
    Roayaie, S
    LIVER TRANSPLANTATION, 2005, 11 (05) : 494 - 496
  • [22] Predictive Models of Hepatocellular Carcinoma Recurrence After Liver Transplantation
    Sanchez Segura, Jose
    Leon Diaz, Francisco Javier
    Perez Reyes, Maria
    Cabano Munoz, Daniel
    Sanchez Perez, Belinda
    Perez Daga, Jose Antonio
    Montiel Casado, Custodia
    Santoyo Santoyo, Julio
    TRANSPLANTATION PROCEEDINGS, 2020, 52 (02) : 546 - 548
  • [23] Needle tract recurrence of hepatocellular carcinoma after liver transplantation
    Dumortier, J
    Lombard-Bohas, C
    Valette, PJ
    Boillot, O
    Scoazec, JY
    Berger, F
    Claudel-Bonvoisin, S
    GUT, 2000, 47 (02) : 301 - 301
  • [24] Recurrence of hepatocellular carcinoma as a mixed hepatoblastoma after liver transplantation
    Dumortier, J
    Bizollon, T
    Chevallier, M
    Ducerf, C
    Baulieux, J
    Scoazec, JY
    Trepo, C
    GUT, 1999, 45 (04) : 622 - 625
  • [25] Clonal Origin of Hepatocellular Carcinoma and Recurrence After Liver Transplantation
    Wang, Zhenglu
    Gong, Weihua
    Shou, Dawei
    Zhang, Luzhou
    Gu, Xiangqian
    Wang, Yuliang
    Teng, Dahong
    Zheng, Hong
    ANNALS OF TRANSPLANTATION, 2016, 21 : 484 - 490
  • [26] Effect of everolimus on hepatocellular carcinoma recurrence after liver transplantation
    Joo, D. J.
    Lee, J. J.
    Kim, D. G.
    Lee, J. G.
    Lee, J.
    Kim, S. H.
    Han, D. H.
    Lee, H. S.
    Ju, M. K.
    Choi, G. H.
    Choi, J. S.
    Kim, M. S.
    Kim, S., I
    TRANSPLANTATION, 2019, 103 (08) : 54 - 55
  • [27] Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
    Fernandez-Sevilla, Elena
    Allard, Marc-Antoine
    Selten, Jasmijn
    Golse, Nicolas
    Vibert, Eric
    Cunha, Antonio Sa
    Cherqui, Daniel
    Castaing, Denis
    Adam, Rene
    LIVER TRANSPLANTATION, 2017, 23 (04) : 440 - 447
  • [28] Antiplatelet Drugs on the Recurrence of Hepatocellular Carcinoma after Liver Transplantation
    Choi, Mun Chae
    Min, Eun-Ki
    Lee, Jae Geun
    Joo, Dong Jin
    Kim, Myoung Soo
    Kim, Deok-Gie
    CANCERS, 2022, 14 (21)
  • [29] Impact of Sirolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation
    Chinnakotla, Srinath
    Davis, Gary L.
    Vasani, Sugam
    Kim, Peter
    Tomiyama, Koji
    Sanchez, Edmund
    Onaca, Nicholas
    Goldstein, Robert
    Levy, Marlon
    Klintmalm, Goeran B.
    LIVER TRANSPLANTATION, 2009, 15 (12) : 1834 - 1842
  • [30] EVEROLIMUS AND SORAFENIB FOR RECURRENCE OF HEPATOCELLULAR CARCINOMA AFTER LIVER TRANSPLANTATION
    De Simone, Paolo
    Pezzati, Daniele
    Lai, Quirino
    Ghinolfi, Davide
    Coletti, Laura
    Precisi, Arianna
    Leonardi, Giulia
    Carrai, Paola
    Filipponi, Franco
    TRANSPLANT INTERNATIONAL, 2013, 26 : 293 - 293